Zealand Pharma A/S
ZEAL
Rank in Stocks
#5570
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Share Price
$34.92
Last synced: 2026-10-21
Market Cap
$2.42B
Change (1 day)
-4.09%
Change (1 year)
-51.75%
Country
DK
Trade Zealand Pharma A/S (ZEAL)
Category
Healthcare
Stock price history for Zealand Pharma A/S (ZEAL)
Highest end of day price: $36.07 on 2026-10-01
Lowest end of day price: $14.13 on 2013-02-01
Lowest end of day price: $14.13 on 2013-02-01
Stock price history of Zealand Pharma A/S from 2013 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -28.90% |
| 2025 | -27.05% |
| 2024 | 103.83% |
| 2023 | 83.97% |
| 2022 | 12.44% |
| 2021 | -30.48% |
| 2020 | 12.58% |
| 2019 | 163.90% |
| 2018 | -13.34% |
| 2017 | -14.27% |
| 2016 | -23.32% |
| 2015 | 66.31% |
| 2014 | 25.21% |
| 2013 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.63 | -4.62% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
